AstraZeneca plans $1.5 billion ADCs manufacturing facility in Singapore

Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs

AstraZeneca sets ambition to deliver US$ 80 billion revenue by 2030

Launch of 20 new medicines expected by 2030

Biocon Biologics’ receives FDA approval for Biosimilar Aflibercept for Yesafili

The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States

Modular ATP study of the mCRM System meets primary safety and efficacy endpoints

Additional data from APPRAISE ATP trial reinforce modular therapy approach

Mankind Pharma launches 'Limit White India' campaign to raise hypertension awareness

Arvinas and Pfizer announce updated clinical data from Phase 1b Trial of Vepdegestrant in combination with Palbociclib

At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months

Cresset opens new new India HQ in Bengaluru to tap potential of APAC market

Cresset’s new India site will support the growing demands of Cresset’s APAC customer base

Biocon signs supply deal with Medix for commercialization of generic Saxenda in Mexico

AbbVie and Gilgamesh Pharmaceuticals collaborate to develop next-gen therapies for psychiatric disorders

Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders

Lonza reports softer performance in Q1 2024

Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s